---
layout: page-fullwidth
show_meta: false
title: ""
subheadline: ""
header: no
permalink: "/publications/"
---

# List of publications

## [On antibacterial drugs for treponematoses therapy](https://curetrep.org/trepab/)

Coming soon.

## [On clinical solutions for SARS-CoV-2](https://curetrep.org/sarscov2/)


* Mitjà, O., *et al* (2021). **A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease**, *The New England Journal of Medicine*, 384:417-427, ([doi](https://www.nejm.org/doi/10.1056/NEJMoa2021801) / [ePrint](https://www.nejm.org/doi/pdf/10.1056/NEJMoa2021801?articleTools=true)).

* Marks, M., *et al* (2021). **Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study**, *The Lancet. Infectious Diseases*, online first, ([doi](https://doi.org/10.1016/S1473-3099(20)30985-3) / [ePrint](https://www.thelancet.com/action/showPdf?pii=S1473-3099%2820%2930985-3)).

* Mitjà, O., *et al* (2020). **Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial**, *Clinical Infectious Diseases* ciaa1009, 1058-4838, ([doi](https://doi.org/10.1093/cid/ciaa1009) / [ePrint](https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa1009/33504392/ciaa1009.pdf)).

* Alemany, A., *et al*. **Analytical and Clinical Performance of the Panbio COVID-19 Antigen-Detecting Rapid Diagnostic Test**, submitted ([ePrint]({{ site.urlimg }}/sarscov2/draft_medvrix.pdf)).

* Suñé, C., *et al*. **Risk factors for mortality of residents in nursing homes with Covid-19: a retrospective cohort study**, submitted ([ePrint]({{ site.urlimg }}/sarscov2/risk_residents.pdf)).


## [On strategies for Yaws eradication](https://curetrep.org/yaws/)

### Selected publications:



* Mitjà, O., *et al* (2018). **Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study**, *The Lancet* 391(10130):1599–1607, ([doi](https://dx.doi.org/10.1016%2FS0140-6736(18)30204-6) / [ePrint](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920722/pdf/nihms942894.pdf)).

* Marks, M., *et al* (2018). **Comparative efficacy of low-dose versus standard-dose azithromycin for patients with yaws: a randomised non-inferiority trial in Ghana and Papua New Guinea**, *The Lancet. Global Health* 6(4):e401-e410, ([doi](https://doi.org/10.1016/s2214-109x(18)30023-8) / [ePrint](https://www.thelancet.com/action/showPdf?pii=S2214-109X%2818%2930023-8)).

* Mitjà, O., *et al* (2017). **Effectiveness of single-dose azithromycin to treat latent yaws: a longitudinal comparative cohort study**, *The Lancet. Global Health* 5(12):e1268-e1274, ([doi](https://doi.org/10.1016/S2214-109X(17)30388-1) / [ePrint](https://www.thelancet.com/action/showPdf?pii=S2214-109X%2817%2930388-1)).

* Mitjà, O., *et al* (2015). **Mass Treatment with Single-Dose Azithromycin for Yaws**, *The New England Journal of Medicine* 372:703-710, ([doi](https://www.nejm.org/doi/10.1056/NEJMoa1408586) / [ePrint](https://www.nejm.org/doi/pdf/10.1056/NEJMoa1408586?articleTools=true)).

* Marks, M., *et al* (2015). **Challenges and key research questions for yaws eradication**, *The Lancet. Infectious diseases* 15(10):1220-1225, ([doi](https://doi.org/10.1016/s1473-3099(15)00136-x) / [ePrint](https://www.thelancet.com/action/showPdf?pii=S2214-109X%2818%2930023-8)).

* Mitjà, O., *et al* (2015). **Global epidemiology of yaws: a systematic review**, *The Lancet. Global Health* 3(6):e324-e331, ([doi](https://www.nejm.org/doi/10.1056/NEJMoa1408586) / [ePrint](https://www.thelancet.com/action/showPdf?pii=S2214-109X%2815%2900011-X)).

* Mitjà, O., *et al* (2014). **Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study**, *The Lancet. Global Health* 2(4):e235-e241, ([doi](https://doi.org/10.1016/S2214-109X(14)70019-1) / [ePrint](https://www.thelancet.com/action/showPdf?pii=S2214-109X%2814%2970019-1)).

* Mitjà, O., *et al* (2014). **Sensitivity and specificity of a rapid point-of-care test for active yaws: a comparative study**, *The Lancet. Global Health* 2(7):e415-e421, ([doi](https://doi.org/10.1016/S2214-109X(14)70231-1) / [ePrint](https://www.thelancet.com/action/showPdf?pii=S2214-109X%2814%2970231-1)).

* Mitjà, O., Asiedu, K. and Prof. Mabey, D. (2013). "Seminar: Yaws", *The Lancet* 381(9868):763-773, ([doi](https://doi.org/10.1016/S0140-6736(12)62130-8) / [Purchase](https://www.thelancet.com/journals/lancet/subscribe?backUri=%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2812%2962130-8%2Ffulltext%3Ffromsource%3Dnelm&offerId=13%2C10.1016%2FS0140-6736%2812%2962130-8&addToCart=true)).

* Mitjà, O., *et al* (2012). **Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial**, *The Lancet* 379(9813):342-347, ([doi](https://doi.org/10.1016/S0140-6736(11)61624-3) / [Purchase](https://www.thelancet.com/journals/lancet/subscribe)).
